Document:

JAZZ Q1 2015 EX 10.3

Exhibit 10.3

2015 Executive Officer Compensation Arrangements 

	
			
	Executive Officer
	Base Salary  
Rate(1)
	Target Bonus as % of Annual Base Salary Rate(2)

	 
	 
	 

	Bruce C. Cozadd 
Chairman and Chief Executive Officer
	$875,000
	100

	 
	 
	 

	Russell J. Cox
Executive Vice President and Chief Operating Officer
	$550,000
	55

	 
	 
	 

	Suzanne Sawochka Hooper
Executive Vice President and General Counsel 
	$500,000
	55

	 
	 
	 

	Matthew P. Young
Executive Vice President and Chief Financial Officer
	$475,000
	55

	 
	 
	 

	Iain McGill
Senior Vice President, Jazz Pharmaceuticals Europe and Rest of World 
	£240,000
	45

	 
	 
	 

	Michael P. Miller
Senior Vice President, U.S. Commercial
	$430,000
	45

	 
	 
	 

	Karen Smith, M.D., Ph.D.
Global Head of Research & Development and Chief Medical Officer
	$475,000
	45

	 
	 
	 

	Paul Treacy
Senior Vice President, Technical Operations
	€250,800
	45

	 
	 
	 

	Karen J. Wilson
Senior Vice President, Finance and Principal Accounting Officer
	$310,000
	45

	 
	 
	 

		
	(1)
	2015 Base salary rates generally effective by March 1, 2015.  Dr. Smith’s base salary rate is effective beginning on April 13, 2015, the commencement date of her employment.

		
	(2)
	Target bonus percentage for each officer is based on his or her position and/or responsibility level as provided in Jazz Pharmaceuticals plc’s cash bonus plans.EX-10.1

 Exhibit 10.1 

Michael Bailey 
 181 Nubble Road 

York, Maine 03909 
 Dear Michael: 

It is with great pleasure that we extend this offer of the position as President and Chief Executive Officer of AVEO Pharmaceuticals, Inc.
(the “Company”). The following sets forth the proposed terms and conditions of your continued employment in the new position as President and Chief Executive Officer. 

1. Position. Your position will be President and Chief Executive Officer, reporting to the Board of Directors of the Company (the
“Board”). If you accept this offer, you will commence the position of Chief Executive Officer effective January 6, 2015. In addition, you will be elected a member of the Board effective upon your commencement of the position of Chief
Executive Officer. 
 2. Compensation and Benefits. Effective as of your start date as Chief Executive Officer, your annual base salary shall
be $425,000, paid semi-monthly in accordance with the Company’s regular payroll practices and subject to applicable tax and other withholdings. You will also be eligible to receive an annual bonus of up to 50% of your base salary, based on
achievement of performance goals, as determined at the discretion of the Board. You will continue to be eligible to participate in the Company’s benefits programs on the same basis as other, similar executives, subject to and in accordance with
the terms of such plans. 
 3. Grant of Options. In connection with your commencement of the President and Chief Executive
Officer position the Board has granted to you a stock option with respect to 900,000 shares of the Company’s common stock, granted under the Company’s stock incentive plan and subject to the terms and conditions set forth in the plan and
the applicable form of option agreement. The option will become exercisable in equal monthly installments over a period of four years commencing on January 6, 2015 and have an exercise price equal to the fair market value of the Company’s
stock on the date of grant of such option. The option will be an incentive stock option, as defined under the Internal Revenue Code, to the maximum extent permitted by law. 

4. Housing Assistance. Beginning with the commencement of your position as President and Chief Executive Officer, the Company will pay
you $5,000 per month, which amount is intended to be used by you for expenses incurred to commute to and live in the Boston area and which amount will be subject to applicable taxes and withholdings. 

5. Existing Agreements. The Severance and Change in Control Agreement, dated as of September 13, 2010 between you and the Company, as
amended by that Retention Bonus Award and Severance Agreement letter dated February 3, 2014 (together, the “Severance Agreement”) shall remain in full force and effect and is hereby affirmed, ratified and continued without amendment
except as specifically set forth herein. In addition, that existing Non-Competition, 

 
Assignment of Inventions and Confidentiality Agreement dated as of September 20, 2010 (the “Confidentiality Agreement”) shall remain in full force and effect and is hereby
affirmed, ratified and continued. Nothing herein shall alter your status as an employee at-will, and both you and the Company remain free to end the employment relationship for any reason, at any time. This letter, together with the Severance
Agreement and the Confidentiality Agreement, constitute the terms and conditions of your employment with the Company. 
 We appreciate all of your efforts
on behalf of the Company and look forward to your enhanced role in the success of the Company. 
 AVEO Pharmaceuticals, Inc. 

Accepted and Agreed By: 
  

	
	 /s/ Tuan Ha-Ngoc

	Tuan Ha-Ngoc
	Chairman of the Board of Directors

  

	
	 /s/ Michael Bailey

	 Michael Bailey
 President and Chief Executive
OfficerEX-10.2

 Exhibit 10.2 

SEVERANCE AND CHANGE IN CONTROL AGREEMENT 

THIS SEVERANCE AND CHANGE IN CONTROL AGREEMENT (the “Agreement”), made this 9th day of January 2015 (the “Effective
Date”), is entered into by AVEO Pharmaceuticals, Inc., a Delaware corporation with its principal place of business at 650 East Kendall Street, Cambridge, MA 02142 (the “Company”), and Michael N. Needle, M.D. (the
“Employee”). 
 WHEREAS, the Company has determined that appropriate steps should be taken to reinforce and encourage the
employment and dedication of the Employee and the Employee’s efforts to maximize the Company’s value. 
 NOW, THEREFORE, as an
inducement for and in consideration of the Employee’s employment with the Company and as consideration for the Employee’s agreement to enter into and be bound by the provisions of Section 4 hereof, the Company agrees that the Employee
shall receive the severance benefits set forth in this Agreement in the event the Employee’s employment with the Company is terminated under the circumstances described below. 

1. Key Definitions. 
 As
used herein, the following terms shall have the following respective meanings: 
 1.1 “Cause” means conduct involving one
or more of the following: (i) the conviction of the Employee of, or, plea of guilty or nolo contendere to, any crime involving dishonesty or any felony; (ii) the willful misconduct by the Employee resulting in material harm to the Company;
(iii) fraud, embezzlement, theft or dishonesty by the Employee against the Company resulting in material harm to the Company; (iv) the repeated and continuing failure of the Employee to follow the proper and lawful directions of the
Company’s Chief Executive Officer or the Board after a written demand is delivered to the Employee that specifically identifies the manner in which the Chief Executive Officer or the Board believes that the Employee has failed to follow such
instructions; (v) the Employee’s current alcohol or prescription drug abuse affecting work performance, or current illegal use of drugs regardless of the effect on work performance; (vi) material violation of the Company’s code
of conduct by the Employee that causes harm to the Company; or (vii) the Employee’s material breach of any term of the Agreement, or any other applicable confidentiality and/or non-competition agreements with the Company. 

1.2 “Good Reason” means the occurrence, without the Employee’s written consent, of any of the following events:
(A) any material diminution in the Employee’s duties, responsibilities or authority, or (B) a material reduction in the Employee’s base salary (unless such reduction is effected in connection with a general and proportionate
reduction of compensation for all employees of his or her level), provided, however, that Good Reason can only occur if (i) the Employee has given the Company a written notice of termination indicating the existence of a condition giving rise
to Good Reason and the Company has not cured the condition giving rise to Good Reason within thirty (30) days after receipt of such notice of termination, and (ii) such notice of termination is given within ninety (90) days after the
initial occurrence of the condition giving rise to Good Reason and further provided that a termination for Good Reason shall occur no more than one hundred eighty (180) days after the initial occurrence of the condition giving rise to Good
Reason. 
 1.3 “Disability” means (i) the Employee is unable to engage in any substantial gainful activity by reason
of any medically determinable physical or mental impairment that can be expected to result in death or can be expected to last for a continuous period of not less than twelve (12) months or (ii) the

 
Employee is, by reason of any medically determinable physical or mental impairment that can be expected to result in death or can be expected to last for a continuous period of not less than
twelve (12) months, receiving income replacement benefits for a period of not less than three (3) months under an accident and health plan covering employees of the Company; provided that in each case, the Employee’s physical or
mental impairment shall be determined by an independent qualified physician mutually acceptable to the Company and the Employee (or his personal representative) or, if the Company and the Employee (or such representative) are unable to agree on an
independent qualified physician, as determined by a panel of three physicians, one designated by the Company, one designated by the Employee (or his personal representative) and one designated by the two physicians so designated. 

2. Termination Without Cause or for Good Reason. 

2.1 Other than as set forth in Section 3 below, if, on or after July 9, 2015, the Employee’s employment with the Company is
terminated by the Company without Cause or due to the Employee’s Disability, or by the Employee for Good Reason, then the Company shall: 

(a) continue to pay the Employee his base salary in effect on the date of termination, to be paid in accordance with the Company’s
customary payroll practices as are established or modified from time to time as follows for the period of time set forth below (the “Severance Period”): 

(i) if the termination occurs on or after July 9, 2015 and prior to January 9, 2016, then Company shall pay the Employee his base
salary until the earlier of (x) the final date of the Initial Severance Period or (y) the date on which the Employee commences employment or a consulting relationship with substantially equivalent compensation; 

(ii) if the termination occurs on or after January 9, 2016, then the Company shall pay the Employee his base salary until the earlier of
(x) the date twelve (12) months following the date of termination, or (y) the date on which the Employee commences employment or a consulting relationship with substantially equivalent compensation; 

For purposes of this Section 2.1, the “Initial Severance Period” shall mean a period having a number of days equal to the number of days that
the Employee has been employed by the Company prior to the date of termination (i.e., January 9, 2015 through his date of termination). 

(b) within thirty (30) days following the execution and non-revocation of the Release (as defined below), pay the
Employee’s target bonus on the date of termination multiplied by a fraction, the numerator of which shall equal the number of days the Employee was employed by the Company during the Company fiscal year in which the termination occurs
and the denominator of which shall equal 365; 
 (c) pay to the Employee (i) on the date of termination, any base salary
earned but not paid and any vacation accrued but not used through the date of termination, and (ii) within thirty (30) days after the date of termination, any reimbursable business expenses incurred by the Employee through the date of
termination pursuant to any expense reimbursement policies of the Company then in effect; and 
 (d) to the extent the
Employee and any qualified beneficiary with respect to such Employee elects continuation of health benefit coverage under Section 4980B (“COBRA”) of the Internal Revenue Code of 1986, as amended (the “Code”), and continues
to be eligible for such benefits, the Company shall provide payments to the Employee for such benefits equal to the amount contributed for active employees with similar benefits and similar participating beneficiaries until the earlier of
(x) the Severance Period (or as long as such eligibility for the Employee and each qualified beneficiary continues), or (y) the date the Employee becomes eligible for group health coverage through another employer. 

 For the avoidance of doubt, if the Employee’s employment terminates for any reason or no reason before
July 9, 2015, the Employee shall not be entitled to any severance payments but shall be entitled to the amounts set forth in Section 2.1(c) above, payable at the time set forth in such Section. 

2.2 The payments and benefits to the Employee under this Section 2 shall (i) be contingent upon the execution and non-revocation by
the Employee of a release of claims (the “Release”) in favor of the Company within sixty (60) days following the date of termination (the “Release Period”), in a form that will be provided by the Company and substantially
identical to the form attached to this Plan as Exhibit A (except for such modifications as the Company may make in its sole discretion to reflect changes in law or the circumstances of the termination); provided that if the Release
does not become effective during the Release Period, the payments and benefits described in Sections 2.1(a) and 2.1(d) of this Agreement that commenced following the date of termination shall cease following the Release Period and
(ii) constitute the sole remedy of the Employee in the event of a termination of the Employee’s employment in the circumstances set forth in this Section 2. 

2.3 Notwithstanding anything herein to the contrary, all benefits under this Section 2 shall terminate immediately if the Employee, at
any time, violates any proprietary information, assignment of inventions agreement, confidentiality, non-competition or non-solicitation obligation to the Company, or any other continuing obligation to the Company. 

3. Termination upon a Change in Control.  

If the Employee is an “Eligible Employee” as defined in the Key Employee Change in Control Severance Plan adopted by the Company in
December 2007, as amended on November 25, 2009 (the current terms of which are attached hereto as Exhibit B) (the “Change in Control Plan”) at the time of a Change in Control, as defined in said Change in Control Plan, then any
termination of the Employee’s employment following such Change in Control shall be governed by the terms of the Change in Control Plan and no benefits shall be provided under the terms of this Agreement; provided, however, that
if the Employee experiences a Qualifying Termination (as defined in the Change in Control Plan) (i) prior to July 9, 2015, then the Employee shall not be eligible for any severance or benefits under the Change in Control Plan or
(ii) on or after July 1, 2015 and prior to January 9, 2016, then the Employee shall be eligible for the payments and benefits set forth in the Change in Control Plan except that that with respect to the payments set forth in
Section 4(a) of the Change in Control Plan, the Severance Multiple shall be multiplied by a fraction the numerator of which is equal to the Initial Severance Period (as defined above) and the denominator of which is 365. 

4. Non-Competition and Non-Solicitation. 

4.1 Restricted Activities. While the Employee is employed by the Company and for a period of one (1) year after the termination or
cessation of such employment for any reason, the Employee will not: 
 (a) directly engage in the development or
commercialization of a Competitive Product for another business or enterprise. For purposes of this provision, a “Competitive Product” means any therapeutic or diagnostic product that competes with any product that the Company
(i) has, as of the date of cessation of the Employee’s employment with the Company, developed to the stage of readiness for a phase 2 clinical trial or later; or (ii) has sold at any time during the Employee’s employment with the
Company or plans to commence selling during the one year period after the cessation of the Employee’s employment; 
 (b)
directly or indirectly either alone or in association with others (i) solicit, or permit any organization directly or indirectly controlled by the Employee to solicit, any employee of the Company to leave the employ of the Company, or
(ii) solicit for employment, hire as an employee 

 
or engage as an independent contractor, or permit any organization directly or indirectly controlled by the Employee to solicit for employment, hire as an employee or engage as an independent
contractor, any person who was employed or engaged by the Company at the time of the termination or cessation of the Employee’s employment with the Company or within six months preceding such termination or cessation; provided, that this
clause (ii) shall not apply to the solicitation, hiring or engagement of any individual whose employment with the Company has been terminated for a period of six months or longer; or 

(c) directly or indirectly make any statements that are professionally or personally disparaging about, or adverse to, the
interests of the Company (including its officers, directors, employees and consultants) including, but not limited to, any statements that disparage any person, product, service, finances, financial condition, capability or any other aspect of the
Company’s business, or engage in any conduct which could reasonably be expected to harm professionally or personally the Company’s business or reputation (including its officers, directors, employees and consultants); provided that these
obligations in Section 4.1(c) will not prevent the Employee from engaging in ordinary business competition with the Company after the provisions of Section 4.1(a) have expired, providing truthful information to any regulatory agency or
providing truthful testimony in any litigation involving the Company or its officers, directors, employees and consultants. 
 If the
Employee violates or breaches any of the provisions of this Section 4.1, then the provisions of this Section 4 shall be applicable to the Employee until a period of one year has expired without any violation or breach of such provisions.

 4.2 Interpretation. If any restriction set forth in Section 4.1 is found by any court of competent jurisdiction to be
unenforceable because it extends for too long a period of time or over too great a range of activities or in too broad a geographic area, it shall be interpreted to extend only over the maximum period of time, range of activities or geographic area
as to which it may be enforceable. 
 4.3 Equitable Remedies. The restrictions contained in this Section 4 are necessary for the
protection of the business and goodwill of the Company and are considered by the Employee to be reasonable for such purpose. The Employee agrees that any breach of this Section 4 is likely to cause the Company substantial and irrevocable damage
which is difficult to measure. Therefore, in the event of any such breach or threatened breach, the Employee agrees that the Company, in addition to such other remedies which may be available, shall have the right to obtain an injunction from a
court restraining such a breach or threatened breach and the right to specific performance of the provisions of this Section 4 and the Employee hereby waives the adequacy of a remedy at law as a defense to such relief. 

5. Taxes.  
 5.1 The
payments set forth in Sections 2 and 3 above shall be subject to the withholding of such amounts, if any, relating to tax and other payroll deductions as the Company determines are reasonably required pursuant to any applicable law or
regulation. Neither the Employee nor the Company shall have the right to accelerate or to defer the delivery of the payments to be made under Sections 2 and 3 of this Agreement. 

5.2 Subject to this Section 5.2, payments or benefits under this Agreement shall begin only upon the date of a “separation from
service” of the Employee (determined as set forth below) which occurs on or after the termination of the Employee’s employment. The following rules shall apply with respect to distribution of the payments and benefits, if any, to be
provided to the Employee under this Agreement: 
 (a) It is intended that each installment of the payments and benefits
provided under this Agreement shall be treated as a separate “payment” for purposes of Section 409A of the Code and 

 
the guidance issued thereunder (“Section 409A”). Neither the Company nor the Employee shall have the right to accelerate or defer the delivery of any such payments or benefits except to
the extent specifically permitted or required by Section 409A; 
 (b) If, as of the date of the “separation from
service” of the Employee from the Company, the Employee is not a “specified employee” (each within the meaning of Section 409A), then each installment of the payments and benefits shall be made on the dates and terms set forth in
this Agreement; 
 (c) If, as of the date of the “separation from service” of the Employee from the Company, the
Employee is a “specified employee” (each, for purposes of this Agreement, within the meaning of Section 409A), then: 

(x) Each installment of the payments and benefits due under this Agreement that, in accordance with the dates and terms set
forth herein, will in all circumstances, regardless of when the separation from service occurs, be paid within the short-term deferral period (as defined in Section 409A) shall be treated as a short-term deferral within the meaning of Treasury
Regulation Section 1.409A-1(b)(4) to the maximum extent permissible under Section 409A; and 
 (y) Each installment
of the payments and benefits due under this Agreement that is not described in Section 5(c)(x) and that would, absent this subsection, be paid within the six-month period following the “separation from service” of the Employee of the
Company shall not be paid until the date that is six months and one day after such separation from service (or, if earlier, the death of the Employee), with any such installments that are required to be delayed being accumulated during the six-month
period and paid in a lump sum on the date that is six months and one day following the Employee’s separation from service and any subsequent installments, if any, being paid in accordance with the dates and terms set forth herein; provided,
however, that the preceding provisions of this sentence shall not apply to any installment of payments and benefits if and to the maximum extent that that such installment is deemed to be paid under a separation pay plan that does not provide for a
deferral of compensation by reason of the application of Treasury Regulation 1.409A-1(b)(9)(iii) (relating to separation pay upon an involuntary separation from service). Such payments shall bear interest at an annual rate equal to the prime rate as
set forth in the Eastern edition of the Wall Street Journal on the Date of Termination, from the Date of Termination to the date of payment. Any installments that qualify for the exception under Treasury Regulation Section 1.409A-1(b)(9)(iii)
must be paid no later than the last day of the second taxable year of the Employee following the taxable year of the Employee in which the separation from service occurs. 

(d) The determination of whether and when a separation from service of the Employee from the Company has occurred shall be made
and in a manner consistent with, and based on the presumptions set forth in, Treasury Regulation Section 1.409A-1(h). Solely for purposes of this Section 5(d), “Company” shall include all persons with whom the Company would be
considered a single employer as determined under Treasury Regulation Section 1.409A-1(h)(3). 
 (e) All reimbursements
and in-kind benefits provided under this Agreement shall be made or provided in accordance with the requirements of Section 409A to the extent that such reimbursements or in-kind benefits are subject to Section 409A, including, where
applicable, the requirements that (i) any reimbursement is for expenses incurred during the Executive’s lifetime (or during a shorter period of time specified in this Agreement), (ii) the amount of expenses eligible for reimbursement
during a calendar year may not affect the expenses eligible for reimbursement in any other calendar year, (iii) the reimbursement of an eligible expense will be made on or before the last day of the calendar year following the year in which the
expense is incurred and (iv) the right to reimbursement is not subject to set off or liquidation or exchange for any other benefit. 

 (f) Notwithstanding anything herein to the contrary, the Company shall have no
liability to the Employee or to any other person if the payments and benefits provided in this Agreement that are intended to be exempt from or compliant with Section 409A are not so exempt or compliant. 

6. Other Employment Termination. If the Employee’s employment terminates for any reason other than as described in
Sections 2 and 3, the Employee shall only receive any compensation owed to such Employee as of the termination date and any other post-termination benefits which the Employee is eligible to receive under any plan or program of the Company. 

7. Successors.  
 7.1
Successor to Company. The Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Company expressly to assume and agree to
perform this Agreement to the same extent that the Company would be required to perform it if no such succession had taken place. All covenants and agreements hereunder shall inure to the benefit of and be enforceable by such successors or assigns
without the necessity that this Agreement be re-signed at the time of such assignment. As used in this Agreement, “Company” shall mean the Company as defined above and any successor to its business or assets as aforesaid which assumes and
agrees to perform this Agreement, by operation of law or otherwise. 
 7.2 Successor to Employee. This Agreement shall inure to the
benefit of and be enforceable by the Employee’s personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees. If the Employee should die while any amount would still be payable to the
Employee or the Employee’s family hereunder if the Employee had continued to live, all such amounts, unless otherwise provided herein, shall be paid in accordance with the terms of this Agreement to the executors, personal representatives or
administrators of the Employee’s estate. 
 8. Notices. All notices, instructions and other communications given hereunder
or in connection herewith shall be in writing. Any such notice, instruction or communication shall be sent either (i) by registered or certified mail, return receipt requested, postage prepaid, or (ii) prepaid via a reputable nationwide
overnight courier service, in each case addressed to the Company, at 650 East Kendall Street, Cambridge, MA 02142, ATTN: Michael Bailey, Chief Executive Officer, and to the Employee at the Employee’s address indicated in the introduction to
this Agreement (or to such other address as either the Company or the Employee may have furnished to the other in writing in accordance herewith). Any such notice, instruction or communication shall be deemed to have been delivered five business
days after it is sent by registered or certified mail, return receipt requested, postage prepaid, or one business day after it is sent via a reputable nationwide overnight courier service. Either party may give any notice, instruction or other
communication hereunder using any other means, but no such notice, instruction or other communication shall be deemed to have been duly delivered unless and until it actually is received by the party for whom it is intended. 

9. Miscellaneous. 

9.1 Employment by Subsidiary. For purposes of this Agreement, the Employee’s employment with the Company shall not be deemed to
have terminated solely as a result of the Employee continuing to be employed by a wholly-owned subsidiary of the Company. 
 9.2
Severability. The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement, which shall remain in full force and effect. 

9.3 Governing Law. The validity, interpretation, construction and performance of this Agreement shall be governed by the internal laws
of the Commonwealth of Massachusetts, without regard to conflicts 

 
of law principles. The Employee hereby irrevocably submits to and acknowledges and recognizes the jurisdiction of the courts of the Commonwealth of Massachusetts, or if appropriate, a
federal court located in Massachusetts (which courts, for purposes of this Agreement, are the only courts of competent jurisdiction), over any suit, action or other proceeding arising out of, under or in connection with this Agreement or
the subject matter hereof. 
 9.4 Waiver of Right to Jury Trial. Both the Company and the Employee expressly waive any right that any
party either has or may have to a jury trial of any dispute arising out of or in any way related to the matters covered by this Agreement. 

9.5 Waivers. No waiver by the Employee at any time of any breach of, or compliance with, any provision of this Agreement to be
performed by the Company shall be deemed a waiver of that or any other provision at any subsequent time. 
 9.6 Counterparts. This
Agreement may be executed in counterparts, each of which shall be deemed to be an original but both of which together shall constitute one and the same instrument. 

9.7 Entire Agreement. Except to the extent provided herein, this Agreement, together with the offer letter and the Invention and
Non-Disclosure Agreement, each to be executed by you and the Company, sets forth the entire agreement of the parties hereto in respect of the subject matter contained herein and supersedes all prior agreements, promises, covenants, arrangements,
communications, representations or warranties, whether oral or written, by any officer, employee or representative of any party hereto in respect of the subject matter contained herein. 

9.8 Not an Employment Contract. The Employee acknowledges that this Agreement does not constitute a contract of employment or impose on
the Company any obligation to retain the Employee as an employee and that this Agreement does not prevent the Employee from terminating employment at any time. 

9.9 Amendments. This Agreement may be amended or modified only by a written instrument executed by both the Company and the Employee,
and, notwithstanding the provisions of the Change in Control Plan, the language of such Change in Control Plan may not be amended as it applies to the Employee except to the extent subject to a written instrument executed by both parties. 

9.10 Employee’s Acknowledgements. The Employee acknowledges that he: (a) has read this Agreement; (b) has been
represented in the preparation, negotiation and execution of this Agreement by legal counsel of the Employee’s own choice or has voluntarily declined to seek such counsel; and (c) understands the terms and consequences of this Agreement.

 9.11 Representations Regarding Prior Work. You represent that you have no agreement or other legal obligation with any prior
employer or any other person or entity that restricts your ability to engage in employment discussion with, employment with or to perform function for, the Company. You represent that you have been advised by the Company that at no time should you
divulge to or use for the benefit of the Company, any trade secret or proprietary information of any previous employer. You acknowledge that you have not divulged or used any such information for the benefit of the Company. You acknowledge that the
Company is basing important business decision on these representations, affirm that all of the statements included herein are true and that any breach of this Section 9.11 would be considered an material breach of this Agreement. 

[Remainder of page intentionally left blank] 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year set
forth above. 
  

							
	AVEO Pharmaceuticals, Inc.	 		  	EMPLOYEE
				
	By:	 	 /s/ Michael Bailey
	 		  	/s/ Michael Needle                                 
                                   
				
	Title:	 	 President and Chief Executive Officer
	 		  	

 EXHIBIT A 

RELEASE 
 Reference is
hereby made to that certain Severance and Change in Control Agreement by and between AVEO Pharmaceuticals, Inc. (the “Company”) and the undersigned dated
[                    ], (the “Agreement”). 

In order to receive the benefits as set forth in the Agreement, I acknowledge that I must enter into this Release and have it become binding
upon me. 
 Except as otherwise set forth in this Release, I hereby release, acquit and forever discharge the Company, its parents and
subsidiaries, and their officers, directors, agents, servants, employees, shareholders, predecessor, successors, assigns and affiliates as well as its and their representatives, agents, insurers and reinsurers, and employee benefit programs (and the
trustees, administrators, fiduciaries and insurers of such programs), past, present and future (hereafter, the “Released Parties”) from any and all claims, charges, complaints, demands, actions, causes of action, suits, rights, debts, sums
of money, costs, accounts, reckonings, covenants, contracts, agreements, promises, doings, omissions, damages, executions, obligations, liabilities, and expenses (including attorneys’ fees and costs), of every kind and nature which I ever had
or now have against the Released Parties, including, but not limited to, those claims arising out of my employment with and/or separation from the Company, including, but not limited to, all claims under Title VII of the Civil Rights Act of 1964, 42
U.S.C. § 2000e et seq., the Age Discrimination in Employment Act, 29 U.S.C. § 621 et seq. (“ADEA”), the Americans With Disabilities Act of 1990, 42 U.S.C. § 12101 et seq., the
Family and Medical Leave Act, 29 U.S.C. § 2601 et seq., the Worker Adjustment and Retraining Notification Act (“WARN”), 29 U.S.C. § 2101 et seq., Section 806 of the Corporate and Criminal Fraud
Accountability Act of 2002, 18 U.S.C. § 1514(A), the Rehabilitation Act of 1973, 29 U.S.C. § 701 et seq., Executive Order 11246, Executive Order 11141, the Fair Credit Reporting Act, 15 U.S.C. § 1681 et
seq., the Employee Retirement Income Security Act of 1974 (“ERISA”), 29 U.S.C. § 1001 et seq., the Massachusetts Fair Employment Practices Act., M.G.L. c. 151B, § 1 et seq., the Massachusetts
Civil Rights Act, M.G.L. c. 12, §§ 11H and 11I, the Massachusetts Equal Rights Act, M.G.L. c. 93, § 102 and M.G.L. c. 214, § 1C, the Massachusetts Labor and Industries Act, M.G.L. c. 149, § 1 et seq., the
Massachusetts Privacy Act, M.G.L. c. 214, § 1B, and the Massachusetts Maternity Leave Act, M.G.L. c. 149, § 105D, all as amended; all common law claims including, but not limited to, actions in tort, defamation and breach of contract; all
claims to any non-vested ownership interest in the Company, contractual or otherwise, including, but not limited to, claims to stock or stock options; and any claim or damage arising out of my employment with or separation from the Company
(including a claim for retaliation) under any common law theory or any federal, state or local statute or ordinance not expressly referenced above; provided, however, that nothing in this Agreement prevents me from filing, cooperating with, or
participating in any proceeding before the Equal Employment Opportunity Commission or a state Fair Employment Practices Agency (except that I acknowledge that I may not be able to recover any monetary benefits in connection with any such claim,
charge or proceeding); provided, further, that nothing in this paragraph shall be construed in any way to release the Company from its obligation to indemnify me from any third party action brought against me based on my employment with the Company,
pursuant to any applicable agreement or applicable law or to reduce or eliminate any coverage I may have under the Company’s director and officer liability policy, if any. 

 I understand and agree that, as a condition for payment to me of the sums set forth in the
Agreement, I shall not make any false, disparaging or derogatory statements to any media outlet, industry group, financial institution or current or former employee, consultant, client or customer of the Company regarding the Company or any of its
directors, officers, employees, agents or representatives or about the Company’s business affairs and financial condition; provided, however, that nothing herein shall prevent me from making truthful disclosures to any
governmental entity or in any litigation or arbitration. 
 In addition, I confirm that I have returned to the Company all keys, files,
records (and copies thereof), equipment (including, but not limited to, computer hardware, software and printers, wireless handheld devices, cellular phones, pagers, etc.), Company identification, Company vehicles and any other Company-owned
property in my possession or control and have left intact all electronic Company documents, including but not limited to, those that I developed or helped develop during my employment. I further confirm that I have cancelled all accounts for my
benefit, if any, in the Company’s name, including but not limited to, credit cards, telephone charge cards, cellular phone and/or pager accounts and computer accounts. 

I acknowledge that I am knowingly and voluntarily waiving and releasing any rights I may have under ADEA. I also acknowledge that the
consideration given under the Agreement for the waiver and release in the preceding paragraph hereof is in addition to anything of value to which I was already entitled. I further acknowledge that I have been advised by this writing, as required by
the ADEA, that: (A) my waiver and release do not apply to any rights or claims that may arise on or after the date I execute this Release; (B) I should consult with an attorney prior to executing this Release; (C) I have been
given more than twenty-one (21) days to consider this Release (although I may choose to voluntarily execute this Release earlier); (D) I have seven (7) days following my execution of this Release to revoke the Release by
notifying the Company; and (E) this Release shall not be effective until the date upon which the revocation period has expired, which shall be the eighth day after this Release is executed by me, provided I have not timely revoked. 

 

			
	Signature:		  

		
	Date:		  

 EXHIBIT B 

AVEO PHARMACEUTICALS, INC. 

KEY EMPLOYEE CHANGE IN CONTROL SEVERANCE BENEFITS PLAN 

SECTION 1. INTRODUCTION 
 The Key Employee
Change in Control Severance Benefits Plan (the “Plan”) is designed to provide separation pay and benefits to certain eligible employees of AVEO Pharmaceuticals, Inc. (“the “Company”) whose employment is involuntarily
terminated without cause or voluntarily terminated for good reason as set forth in this Plan. 
 SECTION 2. DEFINITIONS 

For purposes of this Plan, the following terms shall have the meanings set forth below: 

(a) “BASE SALARY” means the annual base salary for an Eligible Employee as in effect on the Change in Control Date, or as increased
thereafter. 
 (b) “BOARD” means the Board of Directors of the Company. 

(c) “CAUSE” means conduct involving one or more of the following: (i) the conviction of the Eligible Employee of, or, plea of
guilty or nolo contendere to, any crime involving dishonesty or any felony; (ii) the willful misconduct by the Eligible Employee resulting in material harm to the Company; (iii) fraud, embezzlement, theft or dishonesty by the Eligible
Employee against the Company resulting in material harm to the Company; (iv) the repeated and continuing failure of the Eligible Employee to follow the proper and lawful directions of the Company’s Chief Executive Officer or the Board
after a written demand is delivered to the Eligible Employee that specifically identifies the manner in which the Chief Executive Officer or the Board believes that the Employee has failed to follow such instructions; (v) the Eligible
Employee’s current alcohol or prescription drug abuse affecting work performance, or current illegal use of drugs regardless of the effect on work performance; (vi) material violation of the Company’s code of conduct by the Eligible
Employee that causes harm to the Company; or (vii) the Eligible Employee’s material breach of any term of the Plan or any applicable written proprietary information, confidentiality, non-competition and/or non-solicitation agreements
with the Company. 
 (d) “CHANGE IN CONTROL” means the occurrence of any of the events set forth in subsections (A) or
(B) below, provided that such event(s) constitute (i) a change in the ownership of the Company (as defined in Treasury Regulation Section 1.409A-3(i)(5)(v)), (ii) a change in effective
control of the Company (as defined in Treasury Regulation Section 1.409A-3(i)(5)(vi)), or (iii) a change in the ownership of a substantial portion of the assets of the Company (as defined in Treasury Regulation
Section 1.409A-3(i)(5)(vii)): 
 (A) when a person, entity or group (within the meaning of Section 13(d)(3) or
14(d)(2) of the Securities Exchange Act of 1934, a amended) acquires beneficial ownership of the Company’s capital stock equal to 50% or more of either: (X) the then-outstanding shares of the Company’s common stock (the
“Outstanding Company Common Stock”) or (Y) the combined voting power of the Company’s then-outstanding securities entitled to vote generally in the election of directors (the “Outstanding Company Voting Securities”)
provided, however, that for purposes of this subsection (A), the following acquisitions of securities shall not constitute a Change in Control: (1) any acquisition of securities directly from the Company (excluding an acquisition of
securities pursuant to the exercise, conversion or exchange of any security exercisable for, convertible into or 

 
exchangeable for common stock or voting securities of the Company, unless the Person exercising, converting or exchanging such security acquired such security directly from the Company or an
underwriter or agent of the Company) or (2) any acquisition of securities by the Company; or 
 (B) upon the
consummation by the Company of a reorganization, merger, consolidation, statutory share exchange or a sale or other disposition of all or substantially all of the assets of the Company in one or a series of transactions (a “Business
Combination”), provided that, in each case, the persons who were the Company’s beneficial owners of the Outstanding Company Common Stock and Outstanding Company Voting Securities immediately prior to such Business Combination do not
beneficially own, directly or indirectly, more than 50% of the then-outstanding shares of common stock and the combined voting power of the then-outstanding securities entitled to vote generally in the election of directors, respectively, of the
resulting or acquiring corporation in such Business Combination (which shall include, without limitation, a corporation which as a result of such transaction owns the Company or substantially all of the Company’s assets either directly or
through one or more subsidiaries) in substantially the same proportions as their ownership, immediately prior to such Business Combination, of the Outstanding Company Common Stock and Outstanding Company Voting Securities, respectively; or 

(C) such time as the Continuing Directors (as defined below) do not constitute a majority of the Board (or, if applicable, the
Board of Directors of a successor corporation to the Company), where the term “Continuing Director” means at any date a member of the Board (i) who was a member of the Board on the effective date of this Plan, or (ii) who was
nominated or elected subsequent to such date by at least a majority of the directors who were Continuing Directors at the time of such nomination or election or whose election to the Board was recommended or endorsed by at least a majority of the
directors who were Continuing Directors at the time of such nomination or election; provided, however, that there shall be excluded from this clause (ii) any individual whose initial assumption of office occurred as a result of an
actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents, by or on behalf of a person other than the Board. 

(e) “CHANGE IN CONTROL DATE” means the first date on which a Change in Control occurs. 

(f) “DISABILITY” means (i) the Eligible Employee is unable to engage in any substantial gainful activity by reason of any
medically determinable physical or mental impairment that can be expected to result in death or can be expected to last for a continuous period of not less than twelve (12) months or (ii) the Eligible Employee is, by reason of any
medically determinable physical or mental impairment that can be expected to result in death or can be expected to last for a continuous period of not less than twelve (12) months, receiving income replacement benefits for a period of not less
than three (3) months under an accident and health plan covering employees of the Company; provided that in each case, the Eligible Employee’s physical or mental impairment shall be determined by an independent qualified physician mutually
acceptable to the Company and the Eligible Employee (or his personal representative) or, if the Company and the Eligible Employee (or such representative) are unable to agree on an independent qualified physician, as determined by a panel of three
physicians, one designated by the Company, one designated by the Eligible Employee (or his personal representative) and one designated by the two physicians so designated. 

(g) “INVOLUNTARY TERMINATION WITHOUT CAUSE” means an Eligible Employee’s dismissal or discharge by the Company (or, if
applicable, by any successor entity) for a reason other than Cause. The termination of employment will not be deemed to be an “Involuntary Termination Without Cause” if such termination occurs as a result of the Eligible Employee’s
voluntary resignation without Good Reason, death or Disability. 

 (i) “MANAGEMENT TEAM” shall include any executive officer, senior vice-president and
vice-president of the Company and other employees of the Company nominated by the Chief Executive Officer and ratified by the Compensation Committee. 

(j) “QUALIFYING TERMINATION” means that an Eligible Employee’s employment terminates due to an Involuntary Termination Without
Cause or a Voluntary Termination for Good Reason, in either case, within eighteen (18) months following a Change in Control Date. 

(k) “SECTION 16 OFFICER” means an executive officer of the Company, other than the Chief Executive Officer, Chief Financial Officer,
Chief Business Officer and Chief Medical Officer, who is considered to an “officer” of the Company within the meaning of Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended and “executive Officer” of the Company
within the meaning of Rule 3b-7 under the Securities Exchange Act of 1934, as amended. 
 (l) “VOLUNTARY TERMINATION FOR GOOD
REASON” means any action by the Company without the Eligible Employee’s prior consent which results in he or she voluntarily terminating his or her employment with the Company (or, if applicable, with any successor entity) after any of the
following are undertaken by the Company (or, if applicable, by any successor entity) without such Eligible Employee’s express consent, provided, however, that a termination for Good Reason can only occur if (i) the Eligible Employee has
given the Company a written notice of termination indicating the existence of a condition giving rise to Good Reason and the Company has not cured the condition giving rise to Good Reason within thirty (30) days after receipt of such notice of
termination, and (ii) such notice of termination is given within ninety (90) days after the initial occurrence of the condition giving rise to Good Reason and further provided that a termination for Good Reason shall occur no more than one
hundred eighty (180) days after the initial occurrence of the condition giving rise to Good Reason: (A) any requirement by the Company that the Eligible Employee perform his or her principal duties outside a radius of 50 miles from
the Company’s Cambridge, Massachusetts location, (B) any material diminution in the Eligible duties, responsibilities or authority; or (C) a material reduction in the Eligible Employee’s base salary (unless such reduction is
effected in connection with a general and proportionate reduction of compensation for all employees of his or her level). 
 SECTION 3. ELIGIBILITY AND
PARTICIPATION 
 An individual is deemed an “Eligible Employee” and, therefore, eligible to participate in the Plan if he or she is
a member of the Company’s Management Team at the time of such individual’s termination of employment with the Company, and such employment terminates due to an event which constitutes a Qualifying Termination. 

SECTION 4. BENEFITS 
 Eligible Employees are
eligible to receive the following benefits on the following conditions: 
 (a) SALARY AND BONUS PAYOUT. Commencing in the first month
following the month of a Qualifying Termination and the Release set forth in Section (f) below becoming binding on the Eligible Employee, Eligible Employee will be paid in periodic installments consistent with the Company’s payroll
procedures as then in effect and continuing for a number of months equal to the product of the Eligible Employee’s “Severance Multiple” (as set forth below) times twelve (12), a total sum equal to: (i) Severance Multiple times
the Eligible Employee’s Base Salary; (ii) the Eligible Employee’s Severance Multiple times his/her target bonus on the date of the Qualifying Termination; and (iii) the Eligible Employee’s target bonus on the date of
termination multiplied by a fraction, the numerator of which shall equal the number of days the Eligible Employee was employed by the Company during the Company fiscal year in which the termination occurs and the denominator of which shall
equal 365. 

 Severance Multiple shall be based on the following: 

 

									
	 Chief Executive Officer
		 	—  	  		 	1.5	  
			
	 Chief Financial Officer, Chief Business Officer, Chief Medical Officer, Section 16 Officer, and any other Eligible Employee
nominated by the CEO and ratified by the Compensation Committee
		 	—  	 		 	1.0	  
			
	 Senior Vice Presidents, Vice Presidents and other Eligible Employees nominated by CEO and ratified by Compensation Committee, other
than those considered Section 16 Officers
		 	—  	 		 	0.5	  

 (b) HEALTH BENEFITS. Provided the Eligible Employee timely elects continued coverage under federal COBRA
law, the Company shall pay, on the Eligible Employee’s behalf, the portion of premiums for the type of group health insurance coverage, including coverage for his or her eligible dependents, that the Company paid prior to his or her termination
of employment for a period following his or her Qualifying Termination based on the Eligible Employee’s level as follows: 
  

									
	 Chief Executive Officer
		 	—  	 		 	18 months	  
			
	 Chief Financial Officer, Chief Business Officer, Chief Medical Officer, Section 16 Officer, and any other Eligible Employee
nominated by the CEO and ratified by the Compensation Committee
		 	—  	 		 	12 months	  
			
	 Senior Vice Presidents, Vice Presidents and other Eligible Employees nominated by CEO and ratified by Compensation Committee, other
than those considered Section 16 Officers
		 	—  	  		 	6 months	  

 provided, however, that the Company will pay such premiums for the Eligible Employee and his/her eligible dependents only for
coverage for which such individual and those dependents were enrolled immediately prior to the Qualifying Termination. The Eligible Employee shall continue to be required to pay that portion of the premium of such group health insurance coverage,
including coverage for his/her eligible dependents that he/she had been required to pay as an active employee immediately prior to the Qualifying Termination of employment (subject to change). For the balance of the period that an Eligible Employee
is eligible to receive coverage under federal COBRA law, the Eligible Employee shall be eligible to maintain coverage for himself/herself and his/her eligible dependents at the Eligible Employee’s own expense in accordance with applicable law.

 (c) EQUITY ACCELERATION. In addition to any other rights that Eligible Employees may have with respect to the acceleration of the vesting
of any stock options or restricted stock awards (“Awards”) granted to such Eligible Employees pursuant to the Company’s 2002 Stock Incentive Plan, as amended (the “2002 Stock Incentive Plan”), or any successor plan,
including without limitation those certain change in control related acceleration rights (upon a termination without cause) approved by the Board on December 11, 2007, and notwithstanding any provision to the contrary contained in the 2002
Stock Incentive Plan, the instrument evidencing any Award or any other agreement between an Eligible Employee and the Company, each such Award shall be immediately exercisable in full and/or free of all restrictions on repurchase, as the case may
be, if the Eligible Employee’s employment with the Company or the acquiring or succeeding corporation is terminated as a result of a Qualifying Termination. 

 (d) EARNED BUT UNPAID BENEFITS. As of the Qualifying Termination date an Eligible Employee
will also be eligible to receive any earned but unpaid benefits including salary earned but unpaid, the annual bonus for the most recently completed financial year and payment for unused accrued vacation. 

(e) RELEASE. To receive benefits under this Plan, an Eligible Employee must execute after the Qualifying Termination a release of claims
in favor of the Company within thirty (30) days following the Eligible Employee’s date of termination, in the form attached to this Plan as Exhibit A and such release must become effective in accordance with its terms (the
“Release”). Notwithstanding the foregoing, if the 30th day following the Eligible Employee’s date of termination occurs in the calendar year following the Eligible Employee’s
termination, then the payments and benefits will commence no earlier than January 1 of such subsequent calendar year. 

(f) TERMINATION OF BENEFITS. Benefits under this Plan shall terminate immediately if an Eligible Employee, at any time, violates any
proprietary information, confidentiality, non-competition or non-solicitation obligation to the Company, or any other continuing obligation to the Company. 

(g) NON-DUPLICATION OF BENEFITS. Eligible Employees are not eligible to receive benefits under this Plan more than one time and are not
eligible to receive benefits under any other Company change in control severance plan, arrangement or agreement. 
 (h) TAX
WITHHOLDING. Any payments that an Eligible Employee receives under this Plan shall be subject to all required tax withholding. 
 (i)
DISTRIBUTIONS. The following rules shall apply with respect to distribution of the payments and benefits, if any, to be provided to the Eligible Employee under this Section 4: 

(A) It is intended that each installment of the payments and benefits provided under Section 4 shall be treated as a
separate “payment” for purposes of Section 409A of the U.S. Internal Revenue Code of 1986, as amended, and the guidance issued thereunder (“Section 409A”). Neither the Company nor the Eligible Employee shall have the right
to accelerate or defer the delivery of any such payments or benefits except to the extent specifically permitted or required by Section 409A; 

(B) If, as of the date of the “separation from service” of the Eligible Employee from the Company, the Eligible
Employee is not a “specified employee” (each within the meaning of Section 409A), then each installment of the payments and benefits shall be made on the dates and terms set forth in Section 4; and 

(C) If, as of the date of the “separation from service” of the Eligible Employee from the Company, the Eligible
Employee is a “specified employee” (each, for purposes of this Agreement, within the meaning of Section 409A), then: 

(x) Each installment of the payments and benefits due under Section 4 that, in accordance with the dates and terms set
forth herein, will in all circumstances, regardless of when the separation from service occurs, be paid within the Short-Term Deferral Period (as hereinafter defined) shall be treated as a short-term deferral within the meaning of Treasury
Regulation Section 1.409A-1(b)(4) to the maximum extent permissible under Section 409A. For purposes of this Agreement, the “Short-Term Deferral Period” means the period ending on the later of the 15th day of the third month
following the end of the Eligible Employee’s tax year in which the Eligible Employee’s separation from service occurs and the 15th day of the third month following the end of the Company’s tax year in which the Eligible
Employee’s separation from service occurs; and 
 (y) Each installment of the payments and benefits due under
Section 4 that is not paid within the Short-Term Deferral Period and that would, absent this subsection, be paid within 

 
the six-month period following the “separation from service” of the Eligible Employee of the Company shall not be paid until the date that is six months and one day after such
separation from service (or, if earlier, the death of the Eligible Employee), with any such installments that are required to be delayed being accumulated during the six-month period and paid in a lump sum on the date that is six months and one day
following the Eligible Employee’s separation from service and any subsequent installments, if any, being paid in accordance with the dates and terms set forth herein; provided, however, that the preceding provisions of this sentence shall not
apply to any installment of payments and benefits if and to the maximum extent that that such installment is deemed to be paid under a separation pay plan that does not provide for a deferral of compensation by reason of the application of Treasury
Regulation 1.409A-1(b)(9)(iii) (relating to separation pay upon an involuntary separation from service) or Treasury Regulation 1.409A-1(b)(9)(v) (relating to reimbursements and certain other separation payments). Such payments shall bear interest at
an annual rate equal to the prime rate as set forth in the Eastern edition of the Wall Street Journal on the Date of Termination, from the Date of Termination to the date of payment. Any installments that qualify for the exception under Treasury
Regulation Section 1.409A-1(b)(9)(iii) must be paid no later than the last day of the second taxable year of the Eligible Employee following the taxable year of the Eligible Employee in which the separation from service occurs. 

SECTION 5. OTHER TERMINATIONS 
 An otherwise
Eligible Employee shall NOT be eligible to receive benefits under this Plan if (i) the Eligible Employee’s employment terminates due to death, Disability or any other reason other than a Qualifying Termination; or (ii) an Eligible
Employee’s employment is terminated within thirty (30) days of his or her refusal to accept an offer of comparable employment by any successor to the Company (provided that “comparable employment” shall mean employment at a
business office the location of which is not violative of Section 2(g)(i), with duties and responsibilities not violative of Section 2(g)(ii) and with a reduction in such Eligible Employee’s base salary not violative of
2(g)(iii)). 
 SECTION 6. CLAIMS PROCEDURE 

Ordinarily, severance benefits will be paid to an Eligible Employee without to having to file a claim or take any action other than signing the
Release as provided in Section 4(f) of this Plan and, where applicable, not revoking the Release during the applicable revocation period. If an Eligible Employee believes that he or she is entitled to severance benefits under the Plan that are
not being paid, he or she may submit a written claim for payment to the Company. Any claim for benefits shall be in writing, addressed to the Company and must be sufficient to notify the Company of the benefit claimed. If such claim is denied, the
Company shall within a reasonable period of time provide a written notice of denial. The notice will include the specific reasons for denial, the provisions of the Plan on which the denial is based, and the procedure for a review of the denied
claim. Where appropriate, it will also include a description of any additional material or information necessary to complete or perfect the claim and an explanation of why that material or information is necessary. Eligible Employees may request in
writing a review of a claim denied by the Company and may review pertinent documents and submit issues and comments in writing to the Company. The Company shall provide a written decision upon such request for review of a denied claim. The decision
of the Company upon such review shall be final. 
 SECTION 7. MISCELLANEOUS 

The Company reserves the right to amend or terminate this Plan at any time; provided however, that this Plan may not be amended or terminated
following the Change in Control Date; and further provided that Section 4(c) of this Plan shall not be amended without the Eligible Employee’s consent unless the Board determines that the amendment, taking into account any other related
action, would not materially 

 
adversely affect the Eligible Employee. This Plan shall be binding upon any surviving entity resulting from a Change in Control and upon any other person who is a successor by merger,
acquisition, consolidation or otherwise to the business formerly carried on by the Company without regard to whether or not such person actively adopts or formally continues the Plan. The Plan shall be interpreted in accordance with the laws of the
Commonwealth of Massachusetts. The Eligible Employee hereby irrevocably submits to and acknowledges and recognizes the jurisdiction of the courts of the Commonwealth of Massachusetts, or if appropriate, a federal court located
in Massachusetts (which courts, for purposes of the Plan, are the only courts of competent jurisdiction), over any suit, action or other proceeding arising out of, under or in connection with the Plan or the subject matter hereof. 

 EXHIBIT A 

RELEASE 
 Certain
capitalized terms used in this Release are defined in the Key Employee Change in Control Severance Plan (the “Plan”) which I have reviewed. 

In order to receive the benefits as set forth in the Plan, I acknowledge that I must enter into this Release and have it become binding upon
me. 
 Except as otherwise set forth in this Release, I hereby release, acquit and forever discharge the Company, its parents and
subsidiaries, and their officers, directors, agents, servants, employees, shareholders, predecessor, successors, assigns and affiliates as well as its and their representatives, agents, insurers and reinsurers, and employee benefit programs (and the
trustees, administrators, fiduciaries and insurers of such programs), past, present and future (hereafter, the “Released Parties”) from any and all claims, charges, complaints, demands, actions, causes of action, suits, rights, debts, sums
of money, costs, accounts, reckonings, covenants, contracts, agreements, promises, doings, omissions, damages, executions, obligations, liabilities, and expenses (including attorneys’ fees and costs), of every kind and nature which I ever had
or now have against the Released Parties, including, but not limited to, those claims arising out of my employment with and/or separation from the Company, including, but not limited to, all claims under Title VII of the Civil Rights Act of 1964, 42
U.S.C. § 2000e et seq., the Age Discrimination in Employment Act, 29 U.S.C. § 621 et seq. (“ADEA”), the Americans With Disabilities Act of 1990, 42 U.S.C. § 12101 et seq., the Family
and Medical Leave Act, 29 U.S.C. § 2601 et seq., the Worker Adjustment and Retraining Notification Act (“WARN”), 29 U.S.C. § 2101 et seq., Section 806 of the Corporate and Criminal Fraud
Accountability Act of 2002, 18 U.S.C. § 1514(A), the Rehabilitation Act of 1973, 29 U.S.C. § 701 et seq., Executive Order 11246, Executive Order 11141, the Fair Credit Reporting Act, 15 U.S.C. § 1681 et
seq., the Employee Retirement Income Security Act of 1974 (“ERISA”), 29 U.S.C. § 1001 et seq., the Massachusetts Fair Employment Practices Act., M.G.L. c. 151B, § 1 et seq., the Massachusetts
Civil Rights Act, M.G.L. c. 12, §§ 11H and 11I, the Massachusetts Equal Rights Act, M.G.L. c. 93, § 102 and M.G.L. c. 214, § 1C, the Massachusetts Labor and Industries Act, M.G.L. c. 149, § 1 et seq., the
Massachusetts Privacy Act, M.G.L. c. 214, § 1B, and the Massachusetts Maternity Leave Act, M.G.L. c. 149, § 105D, all as amended; all common law claims including, but not limited to, actions in tort, defamation and breach of contract; all
claims to any non-vested ownership interest in the Company, contractual or otherwise, including, but not limited to, claims to stock or stock options; and any claim or damage arising out of my employment with or separation from the Company
(including a claim for retaliation) under any common law theory or any federal, state or local statute or ordinance not expressly referenced above; provided, however, that nothing in this Agreement prevents me from filing, cooperating with, or
participating in any proceeding before the Equal Employment Opportunity Commission or a state Fair Employment Practices Agency (except that I acknowledge that I may not be able to recover any monetary benefits in connection with any such claim,
charge or proceeding); provided, further, that nothing in this paragraph shall be construed in any way to release the Company from its obligation to indemnify me from any third party action brought against me based on my employment with the Company,
pursuant to any applicable agreement or applicable law or to reduce or eliminate any coverage I may have under the Company’s director and officer liability policy, if any. 

I understand and agree that, as a condition for payment to me of the Plan benefits, I shall not make any false, disparaging or derogatory
statements to any media outlet, industry group, financial institution or current or former employee, consultant, client or customer of the Company regarding the Company or any of its directors, officers, employees, agents or representatives or about
the Company’s business affairs 

 
and financial condition; provided, however, that nothing herein shall prevent me from making truthful disclosures to any governmental entity or in any litigation or arbitration.

 I confirm that I have returned to the Company all keys, files, records (and copies thereof), equipment (including, but not limited to,
computer hardware, software and printers, wireless handheld devices, cellular phones, pagers, etc.), Company identification, Company vehicles and any other Company-owned property in my possession or control and have left intact all electronic
Company documents, including but not limited to, those that I developed or helped develop during my employment. I further confirm that I have cancelled all accounts for my benefit, if any, in the Company’s name, including but not limited to,
credit cards, telephone charge cards, cellular phone and/or pager accounts and computer accounts. 
 I acknowledge that I am knowingly and
voluntarily waiving and releasing any rights I may have under ADEA. I also acknowledge that the consideration given under the Plan for the waiver and release in the preceding paragraph hereof is in addition to anything of value to which I was
already entitled. I further acknowledge that I have been advised by this writing, as required by the ADEA, that: (A) my waiver and release do not apply to any rights or claims that may arise on or after the date I execute this Release;
(B) I should consult with an attorney prior to executing this Release; (C) I have been given more than twenty-one (21) days to consider this Release (although I may choose to voluntarily execute this Release earlier); (D) I
have seven (7) days following my execution of this Release to revoke the Release by notifying the Company; and (E) this Release shall not be effective until the date upon which the revocation period has expired, which shall be the eighth
day after this Release is executed by me, provided I have not timely revoked. 
  

			
	 Signature:
		  

		
	 Date:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00244-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00244-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00244-of-00352.parquet"}]]